From: HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities
 | Outcomes of HPV detection and typing, N/% (95% C.I) | |||||
---|---|---|---|---|---|---|
 | HPV- | HPV+ | HR-HPV+ | LR-HPV+ | UR-HPV+ | Total (%) |
Totala | 162/27.2% (23.8–30.9) | 434/72.8% (69.1–76.2) | 258/59.4% (54.8–64) | 151/34.8% (30.5–39.4) | 25/5.8% (3.9–8.4) | 596 (100%) |
Agea (years) | Â | Â | Â | Â | Â | Â |
  ≤ 25 | 15/15.3% (9.4–23.8) | 83/84.7% (76.2–90.6) | 52/62.6% (51.9–72.3) | 31/37.4% (27.7–48.1) | 0 (0%) (<0.01–7.2) | 98 (100%) |
 26–35 | 48/23.1% (17.9–29.3) | 160/76.9% (70.7–82.2) | 98/61.3% (53.5–68.5) | 54/33.7% (26.9–41.4) | 8/5% (2.4–9.7) | 208 (100%) |
 36–45 | 49/36.6% (28.9–45) | 85/63.4% (55–71.1) | 48/56.5% (45.9–66.5) | 28/32.9% (23.9–43.5) | 9/10.6% (5.5–19.1) | 134 (100%) |
  ≥ 46 | 50/32.1% (25.2–-39.7) | 106/67.9% (60.3–74.8) | 60/56.6% (47.1–65.7) | 38/35.8% (27.4–45.3) | 8/7.6% (3.7–14.4) | 156 (100%) |
Cytologyb | Â | Â | Â | Â | Â | Â |
 ASCUS | 66/26% (21–31.7) | 188/74% (68.3–79) | 117/62.2% (55.1–68.9) | 62/33% (26.7–40) | 9/4.8% (2.4–9) | 254 (100%) |
 L-SIL | 10/14.1% (7.6–24.2) | 61/85.9% (75.8–92.4) | 37/60.7% (48.1–72) | 22/36.1% (25.2–48.6) | 2/3.2% (0.3–11.9) | 71 (100%) |
 H-SIL | 4/17.4% (6.4–37.7) | 19/82.6% (62.3–93.6) | 11/57.9% (36.2–76.9) | 7/36.8% (19.1–59.1) | 1/5.3% (<0.01–26.5) | 23 (100%) |